Pregnancy is always a special situation where every action or side effect of the drug varies when compared to a situation of a non-pregnant patient. It is not only because the pregnant woman's metabolism differs due to the hormonal and other changes happened to her, but also because every medicine or its metabolite passes to the baby and shows its action there. The only thing is, be cautious, attentive and well supervised when you take any single drug in pregnancy. The interactions can vary in pregnancy, and the dosage may differ as well. Strict supervision of the Physician is mandatory.
sponsored
Doxamicina has been assigned to pregnancy category C by the FDA. In animal studies, Doxamicina was teratogenic and embryotoxic in rabbits, but not teratogenic in rats. There are no controlled data in human pregnancy. Doxamicina crosses the placenta and should only be given during pregnancy when benefit outweighs risk.
See references
Doxamicina breastfeeding
When a drug is taken when the patient is breast feeding, a part of the drug is secreted in her breast milk and is passed to the baby. The dosage of the medicine to mother and baby are different, and many drugs actions are side effects when you take them without a disease, and what if you the baby takes them without a disease? What if the drug is contraindicated in newborns, infants or children? So, breastfeeding is a very alarming situation when the mother is on medications. Ask your Physician or Pediatrician about the effect of the drug on the baby and how much is excreted in breast milk and if it harms the baby!
Doxamicina is excreted into human milk in small amounts (milk-to-plasma ratio 0.17 to 0.18). The possibility of bowel flora modification and interference with culture results should be considered. The manufacturer recommends that caution be used when administering Doxamicina to breast-feeding women.
See references
References for pregnancy information
Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 7th ed." Philadelphia, PA: Lippincott Williams & Wilkins (2005):
